预防性抗病毒治疗对乙型肝炎表面抗原阳性非小细胞肺癌患者肝功能及乙型肝炎病毒再激活的影响  

Effect of prophylactic antiviral therapy on liver function and reactivation of hepatitis B virus in patients with hepatitis B surface antigen positive non-small cell lung cancer

作　　者：李艳红 赵敏 崔慧敏 张雪莲 LI Yanhong;ZHAO Min;CUI Huimin;ZHANG Xuelian(Department of Infectious Diseases,Zhumadian Central Hospital,Zhumadian 463000,He’nan,China)

机构地区：[1]驻马店市中心医院感染性疾病科,河南驻马店4630000

出　　处：《癌症进展》2022年第1期56-58,62,共4页Oncology Progress

摘　　要：目的探讨预防性抗病毒治疗对乙型肝炎表面抗原(HBsAg)阳性非小细胞肺癌患者肝功能及乙型肝炎病毒(HBV)再激活的影响。方法根据是否采用预防性抗病毒治疗将80例HBsAg阳性非小细胞肺癌患者分为观察组(n=40)和对照组(n=40),两组患者均进行抗肿瘤治疗,观察组患者同时服用抗病毒治疗药物,对照组患者未服用抗病毒治疗药物。比较两组患者的肝功能指标[丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)]、HBV再激活率、肝功能损伤发生率以及抗肿瘤治疗延迟或中断情况。结果抗肿瘤治疗后,两组患者的ALT、AST、TBIL均高于本组治疗前,且观察组患者的ALT、AST、TBIL均低于对照组,差异均有统计学意义(P<0.05)。抗肿瘤治疗后,观察组患者的HBV再激活率、肝功能损伤发生率及抗肿瘤治疗延迟或中断率均明显低于对照组(P<0.01)。结论给予HBsAg阳性非小细胞肺癌患者预防性抗病毒治疗,可有效降低肝功能损伤风险,为患者的抗肿瘤治疗提供更加安全的保障。Objective To investigate the effect of prophylactic antiviral therapy on liver function and reactivation of hepatitis B virus(HBV)in patients with hepatitis B surface antigen(HBsAg)positive non-small cell lung cancer.Method 80 HBsAg positive non-small cell lung cancer patients were divided into observation group(n=40,given anti-tumor therapy and prophylactic antiviral therapy)and control group(n=40,given anti-tumor therapy).Liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST)and total bilirubin(TBIL)],HBV reactivation rate,incidence of liver function injury,and delay or interruption of anti-tumor therapy were compared between the two groups.Result After anti-tumor therapy,the ALT,AST and TBIL levels in the two groups were higher than those before treatment,with lower levels in the observation group than those in the control group(P<0.05).After anti-tumor therapy,the HBV reactivation rate,the incidence of liver function injury and the delay or interruption rate of anti-tumor therapy in the observation group were significantly lower than those in the control group(P<0.01).Conclusion Prophylactic antiviral therapy for HBsAg positive non-small cell lung cancer patients can effectively reduce the risk of liver function injury,and provide a safer guarantee for anti-tumor therapy.

关 键 词：预防性抗病毒治疗 非小细胞肺癌 乙型肝炎表面抗原 肝功能 

分 类 号：R734.2[医药卫生—肿瘤]